Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus sublingual rapamycin bioavailability study in healthy adults
ACTRN12626000421336Phase 4Not yet recruiting
- Sponsor
- Australian Longevity Institute
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus (2 arms), sponsored by Australian Longevity Institute. Primary endpoints: Bioavailability of oral versus sublingual rapamycin and Whole blood immune transcriptomic response. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sirolimus
Beyond the preview
Go deeper on ACTRN12626000421336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000421336.